newsfilter
← Latest News
PR Newswire·

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...